Amneal Pharmaceuticals, Inc. - FORM S-1/A - EX-23.3 - April 13, 2018

Attached files

file filename
EX-23.2 - EX-23.2 - Amneal Pharmaceuticals, Inc.d414240dex232.htm
EX-21.1 - EX-21.1 - Amneal Pharmaceuticals, Inc.d414240dex211.htm
EX-10.18 - EX-10.18 - Amneal Pharmaceuticals, Inc.d414240dex1018.htm
EX-10.17 - EX-10.17 - Amneal Pharmaceuticals, Inc.d414240dex1017.htm
EX-10.16 - EX-10.16 - Amneal Pharmaceuticals, Inc.d414240dex1016.htm
EX-10.15 - EX-10.15 - Amneal Pharmaceuticals, Inc.d414240dex1015.htm
EX-10.14 - EX-10.14 - Amneal Pharmaceuticals, Inc.d414240dex1014.htm
EX-10.13 - EX-10.13 - Amneal Pharmaceuticals, Inc.d414240dex1013.htm
EX-10.12 - EX-10.12 - Amneal Pharmaceuticals, Inc.d414240dex1012.htm
EX-10.11 - EX-10.11 - Amneal Pharmaceuticals, Inc.d414240dex1011.htm
EX-10.10 - EX-10.10 - Amneal Pharmaceuticals, Inc.d414240dex1010.htm
EX-10.9 - EX-10.9 - Amneal Pharmaceuticals, Inc.d414240dex109.htm
EX-10.8 - EX-10.8 - Amneal Pharmaceuticals, Inc.d414240dex108.htm
EX-10.7 - EX-10.7 - Amneal Pharmaceuticals, Inc.d414240dex107.htm
EX-10.6 - EX-10.6 - Amneal Pharmaceuticals, Inc.d414240dex106.htm
EX-10.5 - EX-10.5 - Amneal Pharmaceuticals, Inc.d414240dex105.htm
EX-10.4 - EX-10.4 - Amneal Pharmaceuticals, Inc.d414240dex104.htm
EX-10.1 - EX-10.1 - Amneal Pharmaceuticals, Inc.d414240dex101.htm
EX-5.1 - EX-5.1 - Amneal Pharmaceuticals, Inc.d414240dex51.htm
EX-4.2 - EX-4.2 - Amneal Pharmaceuticals, Inc.d414240dex42.htm
EX-4.1 - EX-4.1 - Amneal Pharmaceuticals, Inc.d414240dex41.htm
EX-3.3 - EX-3.3 - Amneal Pharmaceuticals, Inc.d414240dex33.htm
EX-3.2 - EX-3.2 - Amneal Pharmaceuticals, Inc.d414240dex32.htm
EX-3.1 - EX-3.1 - Amneal Pharmaceuticals, Inc.d414240dex31.htm
EX-2.4 - EX-2.4 - Amneal Pharmaceuticals, Inc.d414240dex24.htm
EX-2.3 - EX-2.3 - Amneal Pharmaceuticals, Inc.d414240dex23.htm
EX-2.2 - EX-2.2 - Amneal Pharmaceuticals, Inc.d414240dex22.htm
EX-2.1 - EX-2.1 - Amneal Pharmaceuticals, Inc.d414240dex21.htm
S-1/A - AMENDMENT NO. 1 TO FORM S-1 - Amneal Pharmaceuticals, Inc.d414240ds1a.htm

Exhibit 23.3

Consent of Independent Registered Public Accounting Firm

We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 7, 2018, in the Amendment No. 1 to the Registration Statement (Form S-1 333-223501) and related Prospectus of Atlas Holdings, Inc. for the registration of 226,738,335 shares of its Class A common stock.

/s/ Ernst & Young LLP

Iselin, New Jersey

April 13, 2018

Amneal Pharmaceuticals, Inc. Reports